Enveric Biosciences Inc. (ENVB) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Enveric Biosciences Inc. (NASDAQ: ENVB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.43 (-2.06% 1D, market cap $6.4M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ENVB ranks #655 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ENVB carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, FBLG (FibroBiologics Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $6.3M) and XCUR (Exicure Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $6.6M). Among the 5-stock peer group, ENVB leads on earnings multiple (N/A) while ENVB leads on capital efficiency (-35.0% ROIC).
Per ENVB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000890821), Enveric Biosciences Inc. generated $0 in revenue, $12.1M in net income, and -$8.1M in free cash flow against $5.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 48.2 (NEUTRAL RANGE)
Capital intensity & 0% operating margin leave 16 pts on the table
While ENVB currently carries a cautious 34/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.46) and Max Pain ($1.50) forces dealer call-delta covering toward $13.91.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Enveric Biosciences Inc. (ENVB) dropped -2.06% to $1.43, trading at 2% of its 52-week range ($1.17 – $13.25). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Pluang report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Pluang report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Pluang report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Pluang report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
https://www.marijuanamoment.net/new-bill-in-congress-would-dramatically-overhaul-how-the-federal-government-classifies-drugs-while-legalizing-marijuana/
Gainers Tempest Therapeutics (NASDAQ:TPST) stock rose 8.9% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $10.1 million. Tenax Therapeutics (NASDAQ:TENX)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ENVB today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ENVB. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Enveric Biosciences Inc. (ENVB) ranks #655 by composite RQD confidence (34/100, grade E) and #924 by equity capitalization ($6.4M). Within this direct 5-issuer industry benchmark cohort, ENVB leads on earnings valuation at N/A trailing P/E, while ENVB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. APRE currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with ENVB at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ENVB
ACTIVE
Enveric Biosciences Inc. | E | 34/100 | — | — | -35.0% | -2.06% | $6.4M | Benchmark Subject |
| FBLG FibroBiologics Inc. | D- | 36/100 | — | — | -35.0% | +0.21% | $6.3M | /fblg-vs-envb → |
| XCUR Exicure Inc. | E | 32/100 | — | — | -35.0% | +8.05% | $6.6M | /xcur-vs-envb → |
| APRE Aprea Therapeutics Inc. | D- | 40/100 | — | — | -35.0% | -1.82% | $6.1M | /apre-vs-envb → |
| BGMS Bio Green Med Solution Inc. | D- | 38/100 | — | — | -35.0% | +8.43% | $6.0M | /bgms-vs-envb → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Enveric Biosciences Inc. (ENVB) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $12.1M, operating cash flow of -$8.1M, and free cash flow of -$8.1M (-5.4% YoY). On the balance sheet, ENVB closed FY2025 with $5.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $12.1M | -$8.1M | -$8.1M | $5.1M | — |
| FY2024 (FY) | 2024-12-31 | $0 | $9.6M | -$7.7M | -$7.7M | $3.1M | — |
| FY2023 (FY) | 2023-12-31 | $0 | $17.5M | -$14.1M | -$14.1M | — | — |
As of 2026-11-03, Enveric Biosciences Inc. (NASDAQ: ENVB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.43 (-2.06% 1D, market cap $6.4M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ENVB ranks #655 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ENVB carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, FBLG (FibroBiologics Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $6.3M) and XCUR (Exicure Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $6.6M). Among the 5-stock peer group, ENVB leads on earnings multiple (N/A) while ENVB leads on capital efficiency (-35.0% ROIC).
Per ENVB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000890821), Enveric Biosciences Inc. generated $0 in revenue, $12.1M in net income, and -$8.1M in free cash flow against $5.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ENVB last traded at $1.43 (-2.06% on volume of 12,003 shares), positioning the stock -2.05% below its 50-day simple moving average ($1.46) and -28.14% below its 200-day simple moving average ($1.99). Across its 52-week range of $1.17 to $13.25, ENVB sits at the 2.2% percentile with a 14-day RSI of 48.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.25 to $1.61).
Why ENVB Stock dropped -2.06% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, ENVB scores 34 out of 100, earning a letter grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:
Taken together, the pillar scores point to weakness in cash generation, insider conviction, and forensic balance-sheet quality. Any upside case rests on factors outside the scored fundamentals, and the market capitalization of $6.5M and a share price of 1.46 against a 52-week range of $1.17 - $13.25 indicate a steep decline over the period. Valuation multiples such as P/E are not available in source data, which limits direct valuation tradeoff analysis.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-8.8M | $12.1M | N/A | $-8.1M | N/A | N/A |
| FY 2024 | $0.0M | $-9.6M | $9.6M | N/A | $-7.7M | N/A | N/A |
| FY 2023 | $0.0M | $-16.4M | $17.5M | N/A | $-14.1M | N/A | N/A |
Per the SEC financials, reported revenue is $0.0M in each period shown, and operating income is negative in all three years. Gross, operating, and net margins are each 0% per the market data. ROIC is -35% per the market data, and the Altman Z-Score of 2.5 and Piotroski F-Score of 3/9 are cited in the Roarable RQD rating. Debt/Equity is 0.5 per the Roarable RQD rating, while cash and debt balances are N/A in the SEC financials.
Per the recent news wire, the headlines include: a report on favorable preclinical results for a non-hallucinogenic psychiatric candidate; a report on positive results from IND-enabling ADMET studies; a securities-fraud lawsuit headline referencing a stock decline at another issuer ("Ensign"), which is not clearly tied to ENVB in the source; a patent-related headline referencing a different company (Microbot Medical); and a seasonal chart headline referencing Acurx Pharmaceuticals. Each item carries a YELLOW light and MARKET WIRE impact label. Watch items include the reliance on preclinical milestones and the presence of unrelated-company headlines in the feed, which limits direct attribution. Per the Butterfly Supply-Chain Graph, the supply chain is "NONE" with no butterfly links and no proprietary signals.
Real-time company headlines, analyst actions, and sector developments for Enveric Biosciences Inc. (ENVB) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Pluang report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Pluang report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Pluang report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Pluang report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering Enveric Biosciences Inc. (ENVB) market action, institutional positioning, and fundamental catalysts.
Welcome to the ENVB (Enveric Biosciences Inc.) Roar Pit. Current RQD Composite is 34/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on ENVB, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Enveric Biosciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on ENVB, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.46 (52-wk range $1.17 - $13.25), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).